In aggregate, these initial filters removed 80 people (0.29%)
We can help determine if an underlying health conditionsuch as polycystic ovary syndrome (PCOS), thyroid disorders, or another hormonal imbalancemay be contributing to these changes
Ziyad Al-Aly of the VA Saint Louis Health Care System in Missouri, who led the study published in The BMJ
After 68 weeks, participants receiving a 2.4 mg weekly semaglutide dose experienced a 49% reduction in C-reactive protein (CRP), while those on a 1 mg weekly dose saw a 42% reduction compared to placebo
When something else is going on medically Stalled weight loss can signal medical issues unrelated to GLP-1 receptor sensitivity
These findings suggest that survodutide has the potential to reduce liver fibrosis and improve liver function in patients with NASH, making it a promising therapeutic option for this complex liver disease [89]